title: [IL-2-receptor associated action of the modified peptide fragments of human IL-2 on macrophages].
abstract: Synthetic peptides corresponding to the 59-72 (I), 60-72 (II) and 61-72 (III) sequences of human interleukin 2 with their N(alpha) acetylated and C(alpha) methylated termini were shown to exhibit pronounced hepatoprotective properties. These peptides neutralized hepatotoxic effects of such agents as tetrachloromethane and galactosamine in experiments in vivo. The peptide action revealed as normalization of duration of the thiopental narcosis of experimental animals and the level of hepatospecific enzymes in their blood. The effects of peptides (I)-(III) proved to be similar to that of prednisolone (the well-known anti-inflammatory agent), whereas the bestatine cytotoxic dipeptide had no hepatoprotecting effect. The target of the hepatoprotective activity of the peptides was shown to be the preliminary activated macrophages. We proposed that this activity of the peptides was associated with their interaction with the a-subunit of the interleukin 2 receptor (IL-2Ralpha), because the X-Ray analysis pointed to this region as one of binding sites of IL-2 with IL-2Ralpha. Experiments on the influence of the most active (59-72)-peptide on growth of the IL-2 dependent cell line (CTLL) confirmed this proposal. The 3H-labeled peptide corresponding to the 59-72 sequence ofthe human IL-2 was shown to bind to the CTLL cels. We assumed that the binding of this peptide was specific and occurred precisely with IL-2Ra and virtually determined the binding constant. Its value (1.41 x 10(-6) M) was comparable with that of the interaction of IL-2 with IL-2Ralpha (approximately 10(-7) M).
authors.forename: L V
authors.initials: LV
authors.lastname: Onoprienko
authors.forename: I I
authors.initials: II
authors.lastname: Mikhaleva
authors.forename: B O
authors.initials: BO
authors.lastname: Voĭtenkov
authors.forename: V T
authors.initials: VT
authors.lastname: Ivanov
mesh_terms: D000818:Animals; D001665:Binding Sites; D002251:Carbon Tetrachloride / Q000633:toxicity; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D005688:Galactosamine / Q000633:toxicity; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D007376:Interleukin-2 / Q000138:chemical synthesis / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D053645:Interleukin-2 Receptor alpha Subunit / Q000737:chemistry / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology; D020011:Protective Agents / Q000138:chemical synthesis / Q000494:pharmacology
chemical_list: D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; D010446:Peptide Fragments; D020011:Protective Agents; D005688:Galactosamine; C046516:interleukin-2 (59-72); D002251:Carbon Tetrachloride